Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.57 |
| ▸ | NPY4R | P50391 | 11/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.55 |
| ▸ | FCER2 | P06734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551485 | 1.00 | MC4R (0.57) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6552897 | 0.97 | NPY4R (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6551966 | 0.97 | NPY4R (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19656447 | 0.94 | NPY4R (0.54) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30029024 | 0.92 | GNPAT (0.56) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL13563435 | 0.92 | KISS1R (0.62) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL12792618 | 0.92 | KISS1R (0.62) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6552721 | 0.91 | CTSL (0.54) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6551464 | 0.91 | MC4R (0.58) | MC4RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6552715 | 0.91 | MC4R (0.58) | MC4RNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147567-A1 | Control appetites; obesity; eating disorders | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1388537-A1 | ARGININE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-11 | — | — | EP | claimed |
| US-20040147567-A1 | Control appetites; obesity; eating disorders | TAISHO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1388537-A1 | ARGININE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147567-A1 | Control appetites; obesity; eating disorders | MC4R, NPY4R, MC5R | MC4R 1/4885NPY4R 2/4885NPY5R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.